Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) has made for a solid investment over the past decade, more than quadrupling in value during that period. The stock generated fantastic returns for ...

Vertex Pharmaceuticals (NASDAQ: VRTX) climbed as much as 32% from the start of the year through the middle of last month. The company was on a roll when it came to good news. Its cystic fibrosis (CF) ...

Vertex’s cystic fibrosis treatments have generated blockbuster revenue over time -- and growth continues. The company now is wrapping up a pivotal program meant to address one of the most common ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is ...

Vertex faced some setbacks with two pipeline programs in acute and neuropathic pain. However, the company still has a path forward for both of those medicines. It has several other pipeline candidates ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director.

BOSTON — Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood ...

Vertex Pharmaceuticals is a leader in cystic fibrosis treatments. The company is working on expanding its business, which will open up more growth opportunities. Its strong financials equip the ...